chemieunternehmen.com

Evotec AG today announced the publication of its fifth DDup edition. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-5—antibiotics-5222

Evotec AG announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-collaborate-with-fraunhofer-in-joint-drug-discovery-programmes-5221

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 1.0 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-5217

Evotec AG today announced the acquisition of all shares in Euprotec Ltd, a UK-based specialist contract research organisation. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-establish-an-anti-infectives-platform-with-the-acquisition-of-euprotec-ltd-5211

Evotec AG today reported financial results and corporate updates for the first quarter of 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-quarter-2014-5209

Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec’s technology platform and broad expertise in drug discovery and pre-clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-eternygen-enter-collaboration-to-identify-and-develop-novel-metabolic-disease-therapy-5205

Evotec AG today announced the successful achievement of a milestone in its biomarker alliance with Roche. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-first-milestone-in-roche-biomarker-collaboration-5203

Evotec AG announced today a research collaboration and licensing deal with Debiopharm GroupTM Lausanne, Switzerland. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-debiopharm-grouptm-to-collaborate-on-development-of-new-treatment-for-cancer-5201

Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-convergence-form-integrated-pain-alliance-5199